title: Effects of methysergide administration on edema formation at the site of scald.
abstract: Femoral blood flow (Qa), hind paw lymph flow (Qlym), and lymph-to-plasma protein concentration ratio (Clym/Cp) were monitored before and 4 h after 1) 5-s 100 degrees C paw scald, 2) methysergide (1 mg/kg iv) 20 min before scald, 3) methysergide 30 min after scald, and 4) methysergide only. Before experimentation, hind paw venous pressure was elevated and maintained until steady-state Qa, Qlym, and minimal Clym/Cp levels were reached. The reflection coefficient (sigma d) was determined as 1 - minimal Clym/Cp; the filtration coefficient (Kf) was calculated. Methysergide alone caused no changes. Increases in Qa, Qlym, Clym/Cp, and Kf were identified in all scald groups. Compared with scald only animals, pre- and postscald methysergide blunted the increases in Qa, Qlym, Kf, and paw weight gain without an effect on sigma d. These data demonstrate that methysergide reduces edema formation at the site of scald, perhaps by modulating the burn-induced vasodilator response and/or by limiting the burn-induced increase in microvascular surface area.
authors.affiliation: Department of Surgery, Tulane University School of Medicine, New Orleans, Louisiana.
authors.forename: J J
authors.initials: JJ
authors.lastname: Ferrara
authors.forename: E W
authors.initials: EW
authors.lastname: Franklin
authors.forename: E U
authors.initials: EU
authors.lastname: Choe
authors.forename: H L
authors.initials: HL
authors.lastname: Lippton
authors.forename: A L
authors.initials: AL
authors.lastname: Hyman
authors.forename: L M
authors.initials: LM
authors.lastname: Flint
mesh_terms: D000818:Animals; D001794:Blood Pressure / Q000187:drug effects / Q000502:physiology; D002056:Burns / Q000473:pathology*; D002199:Capillary Permeability / Q000187:drug effects; D002463:Cell Membrane Permeability / Q000187:drug effects; D004285:Dogs; D004487:Edema / Q000473:pathology / Q000517:prevention & control*; D005263:Femoral Artery / Q000187:drug effects; D005528:Foot / Q000473:pathology; D008196:Lymph / Q000187:drug effects; D008784:Methysergide / Q000627:therapeutic use*; D012039:Regional Blood Flow / Q000187:drug effects; D012702:Serotonin Antagonists / Q000494:pharmacology
chemical_list: D012702:Serotonin Antagonists; D008784:Methysergide